24/7 Market News Snapshot 12 September, 2025 – Cocrystal Pharma, Inc. Common Stock (NASDAQ:COCP)

September 12, 2025

DENVER, Colo., 12 September, 2025 (www.247marketnews.com) – (NASDAQ:COCP) are discussed in this article.
Cocrystal Pharma, Inc. experienced a notable market response today, with shares opening at $2.45 but subsequently trading down to $1.60, marking an 11.18% decline from the previous day’s closing price. This drop in stock value suggests a bearish outlook among investors, potentially influenced by various factors affecting overall company performance or broader sector dynamics. Current trading volume has reached an impressive 68.53 million shares, indicating increased investor activity possibly in reaction to recent news. Technical indicators highlight potential support near $1.50 and resistance around the opening price, signaling crucial levels for investors to monitor.

In a strategic move to bolster its financial standing, Cocrystal has entered into definitive agreements to issue approximately 2,764,710 shares of common stock at $1.70 per share, aiming to raise gross proceeds of roughly $4.7 million. This registered direct offering, conducted in accordance with Nasdaq regulations, will also involve the issuance of unregistered warrants, which could generate an additional $8.3 million if fully exercised. Expected to close around September 15, 2025, the offering is subject to standard closing conditions and has been placed under the guidance of H.C. Wainwright & Co. as the exclusive placement agent.

The proceeds from this capital raise are intended for general corporate purposes and working capital, reflecting Cocrystal’s focus on advancing its innovative antiviral treatment pipeline. The company’s commitment to addressing critical unmet medical needs is evident in its efforts to develop therapies targeting influenza, viral gastroenteritis, COVID-19, and hepatitis through its cutting-edge structure-based technologies. The issuance of these shares and warrants demonstrates Cocrystal’s dedication to financial transparency and regulatory compliance while enhancing its capacity to drive forward its strategic initiatives in biotechnology.

Related news for (COCP)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.